In this CME-certified activity, Bradley J. Monk, MD, FACS, FACOG, reviews key data supporting treatment advances in ovarian cancer, including optimal chemotherapy, VEGF inhibition, PARP inhibition, and more.
In this downloadable slideset, Bradley J. Monk, MD, FACS, FACOG, reviews key data supporting treatment advances in ovarian cancer, including optimal use of chemotherapy, VEGF inhibitors, PARP inhibitors, and more.
Among the gynecologic cancer studies presented at ASCO, these are the ones that I feel have the most potential to influence clinical practice.
In this commentary, I share my thoughts on recent clinical data and how clinicians can make the best use of both bevacizumab and PARP inhibitors in treating their patients with advanced ovarian cancer.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.